Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach.
Bottom Line: Loss of αGlcNAc was also significantly associated with poorer patient prognosis in MUC6-positive differentiated-type adenocarcinoma.In undifferentiated-type adenocarcinoma, we observed no significant correlation between mucin phenotypic marker expression, including MUC6, and any clinicopathologic variable.These results together indicate that loss of αGlcNAc in MUC6-positive cancer cells is associated with progression and poor prognosis in differentiated, but not undifferentiated, types of gastric adenocarcinoma.
Affiliation: Department of Molecular Pathology, Shinshu University Graduate School of Medicine, Matsumoto, Japan; Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan.Show MeSH
Related in: MedlinePlus
Mentions: Expression of αGlcNAc in gastric cancer was heterogeneous, irrespective of the histological types. As shown previously,25,32 and further confirmed here, αGlcNAc-positive cancer cells tended to be located in the lower layer of the gastric mucosa rather than in the upper layer, regardless of differentiated or undifferentiated types (Fig.4a,c). Once the cancer cells invaded beyond the muscularis mucosae, αGlcNAc-positive cancer cells were irregularly distributed throughout carcinoma tissues, and the expression levels of αGlcNAc in the invasive region tended to mirror the expression levels of the glycan in the intramucosal cancer region within the same tumor (Fig.4b,c).
Affiliation: Department of Molecular Pathology, Shinshu University Graduate School of Medicine, Matsumoto, Japan; Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan.